Literature DB >> 15133327

Osteoporosis and urolithiasis.

R Caudarella1, F Vescini, A Buffa, G La Manna, S Stefoni.   

Abstract

Several studies have indicated that up to 60% of idiopathic calcium stone formers present hypercalciuria. Many authors have described reduced bone mineral density (BMD) in stoneformers with hypercalciuria, but osteopenia has also been found in normocalciuric patients. Moreover, Jaeger's group found that bone mass was reduced in all patients with calcium stone disease, independently of hypercalciuria. Many factors may contribute to the pathogenesis of osteopenia in stone formers. A predominant role has been given to the low-calcium diet that is still prescribed in nephrolithiasis. Also slight metabolic acidosis, which is frequently present in stone formers eating a diet rich in animal protein, can contribute to bone loss. Finally, some authors described a pathogenetic role for cytokines, prostaglandins and vitamin D receptor gene polymorphisms. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15133327     DOI: 10.1159/000076585

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  17 in total

1.  Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study.

Authors:  S-M Ou; Y-T Chen; C-J Shih; D-C Tarng
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

2.  Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics.

Authors:  Gerhard J Molderings; Gerold Solleder; Ulrich W Kolck; Jürgen Homann; Detlev Schröder; Ivar von Kügelgen; Roland Vorreuther
Journal:  Urol Res       Date:  2009-06-10

Review 3.  Randall's plaques, plugs and the clinical workup of the renal stone patient.

Authors:  Pietro Manuel Ferraro; Ferraro Pietro Manuel; Alessandro D'Addessi; D'Addessi Alessandro; Giovanni Gambaro; Gambaro Giovanni
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

4.  Bone and metabolic markers in women with recurrent calcium stones.

Authors:  Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Salvador Arias-Santiago
Journal:  Korean J Urol       Date:  2013-03-15

5.  Osteopenia/osteoporosis in patients with calcium nephrolithiasis.

Authors:  Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Maria Sierra Girón-Prieto; Antonio Poyatos-Andujar; Juan Garrido-Gomez; Armando Zuluaga-Gomez; Salvador Arias-Santiago
Journal:  Urol Res       Date:  2012-08-12

6.  Bisphosphonates in children with hypercalciuria and reduced bone mineral density.

Authors:  Michael Freundlich; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

Review 7.  Biomolecular mechanism of urinary stone formation involving osteopontin.

Authors:  Kenjiro Kohri; Takahiro Yasui; Atsushi Okada; Masahito Hirose; Shuzo Hamamoto; Yasuhiro Fujii; Kazuhiro Niimi; Kazumi Taguchi
Journal:  Urol Res       Date:  2012-11-06

8.  Bone remodeling markers as lithogenic risk factors in patients with osteopenia-osteoporosis.

Authors:  María Sierra Girón-Prieto; Salvador Arias-Santiago; María Del Carmen Cano-García; Antonio Poyatos-Andújar; Tomás de Haro-Muñoz; Felix Abad-Menor; Miguel Quesada-Charneco; Miguel Ángel Arrabal-Polo; Miguel Arrabal-Martín
Journal:  Int Urol Nephrol       Date:  2016-07-04       Impact factor: 2.370

9.  Microscopic hematuria is associated with low bone mineral density in aged women and men.

Authors:  Kazutoshi Nakamura; Junichiro James Kazama; Yoshifumi Tanaka; Keiko Makabe; Mari Oyama; Yasuo Tsuchiya; Masaharu Yamamoto
Journal:  J Bone Miner Metab       Date:  2009-01-20       Impact factor: 2.626

10.  Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Prasad L Gawade; Kirsten K Ness; Shelly Sharma; Zhenghong Li; Deo Kumar Srivastava; Sheri L Spunt; Kerri Nottage; Matthew J Krasin; Melissa M Hudson; Sue C Kaste
Journal:  J Cancer Surviv       Date:  2012-09-06       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.